| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.89 | 1-year : | 1.04 |
| Resists | First : | 0.76 | Second : | 0.89 |
| Pivot price | 0.76 | |||
| Supports | First : | 0.76 | Second : | 0.76 |
| MAs | MA(5) : | 0.76 | MA(20) : | 0.76 |
| MA(100) : | 0.76 | MA(250) : | 0.9  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 45.8 | |||
| 52-week | High : | 2.34 | Low : | 0.66 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GENE ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.77 - 0.77 | 0.77 - 0.77 |
| Low: | 0.75 - 0.76 | 0.76 - 0.76 |
| Close: | 0.76 - 0.77 | 0.77 - 0.77 |
Fri, 26 Sep 2025
NIH Funds New Autism Studies on Genes and Environment as Trump Focuses on Tylenol - Scientific American
Fri, 26 Sep 2025
Biogen officially ends all AAV gene therapy work, prompting team restructure - Fierce Biotech
Fri, 26 Sep 2025
She was the world’s oldest person, living to 117. What do her genes reveal about the secret of longevity? - CNN
Thu, 25 Sep 2025
Rare gene impacts family twice - Alaska's News Source
Thu, 25 Sep 2025
Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies - Reuters
Thu, 25 Sep 2025
FDA Details Thinking for Streamlining Development of Cell, Gene, Regenerative Therapies - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 5 (M) |
| Shares Float | 28 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | -0.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -124.3 % |
| Operating Margin | -113.2 % |
| Return on Assets (ttm) | -63 % |
| Return on Equity (ttm) | -185 % |
| Qtrly Rev. Growth | -10.7 % |
| Gross Profit (p.s.) | 1.21 |
| Sales Per Share | 1.99 |
| EBITDA (p.s.) | -2.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -38.25 |
| PEG Ratio | 0 |
| Price to Book value | 76.5 |
| Price to Sales | 0.38 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|